Tocilizumab
CAS No. 375823-41-9
Tocilizumab ( —— )
产品货号. M22142 CAS No. 375823-41-9
Tocilizumab (抗 IL-6R) 是一种人源化单克隆抗体,可与白细胞介素 6 受体结合。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥2214 | 有现货 |
|
| 5MG | ¥3781 | 有现货 |
|
| 10MG | ¥5396 | 有现货 |
|
| 25MG | ¥8110 | 有现货 |
|
| 50MG | ¥10881 | 有现货 |
|
| 100MG | ¥14220 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Tocilizumab
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述Tocilizumab (抗 IL-6R) 是一种人源化单克隆抗体,可与白细胞介素 6 受体结合。
-
产品描述Tocilizumab anti-IL-6R) is a humanized monoclonal antibody that binds to the interleukin-6 receptor.
-
体外实验Cell Proliferation Assay Cell Line:Human-derived HARA-B cells Concentration:1 ng/mL, 10 ng/mL, and 100 ng/mL Incubation Time:24 hours, 48 hours Result:Inhibited the IL-6R expressed on human-derived HARA-B cells.Cell Cytotoxicity Assay Cell Line:Ba/F3-gp130-IL-6R cells Concentration:0.001–10000 μg/ml Incubation Time:2 days Result:Inhibited Ba/F3-gp130-IL-6R cell proliferation. Western Blot Analysis Cell Line:SAS cells Concentration:1 μM Incubation Time:6 hours Result:Reduced the phosphorylation of STAT3.RT-PCR Cell Line:SAS cells Concentration:1-5 μM Incubation Time:24 hoursResult:Reduced VEGF mRNA expression.
-
体内实验Animal Model:A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice Dosage:1.0 mg/100 μL Administration:Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks Result:Led the volume of each metastatic focus significantly smaller.Animal Model:SCID mice with SAS cells Dosage:100 μg/mL Administration:Intraperitoneal injection;100 μg/mL; every 48 hours; 20days Result:Suppressed the growth of advanced tumors.
-
同义词——
-
通路Apoptosis
-
靶点IL Receptor
-
受体IL Receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number375823-41-9
-
分子量148 kDa
-
分子式——
-
纯度>98% (HPLC)
-
溶解度——
-
SMILES——
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70
产品手册
关联产品
-
Tildrakizumab
Tildrakizumab (SCH 900222) 是一种人源化抗-IL-23 (p19 亚基) 单克隆抗体。IL-23 是维持 Th17 细胞表型的关键细胞因子。Tildrakizumab 对单链 IL-23 具有高亲和力 (Kd: 136 pM)。Tildrakizumab 对中度至重度斑块状银屑病有效。
-
Kaempferol 3-O-β-D-g...
山奈酚 3-O-β-D-葡萄糖醛酸具有抗氧化活性。类黄酮葡萄糖醛酸苷可以被多种人体细胞的微粒体 α2-葡萄糖醛酸酶解偶联。
-
Brodalumab
Brodalumab (AMG 827) 是一种抗人白介素 17 受体 (IL-17R) IgG2 单克隆抗体,可用于研究中重度斑块性银屑病和类风湿性关节炎。
021-51111890
购物车()
sales@molnova.cn

